Telemedicine Appointments Available! 

 Coming soon Retatrutide - Semaglutide 10, 12.5 or 25mg vials  - Tirzepatide 60, 75 or 180mg vials

We will be closed Monday May 27th for Memorial Day 


Telemedicine Appointments Available! 

 Coming soon Retatrutide - Semaglutide 10, 12.5 or 25mg vials  - Tirzepatide 60, 75 or 180mg vials

We will be closed Monday May 27th for Memorial Day 

blue measuring tape with colorful pills on table


Screen Shot 2021-08-19 at 1.19.38 PM

The FDA approved Imcivree (setmelanotide) for chronic weight management in patients six years and older with obesity due to 3 genetic conditions: pro-opiomelanocortin (POMC) deficiency, proprotein subtilisin/kexin type 1 (PCSK1) deficiency, and leptin receptor (LEPR) deficiency. POMC, PCSK1 or LEPR deficiency affect the melanocortin 4 receptor (MC4R) pathway which is responsible for transmission of signals about when to eat and when to stop eating. Patients with these deficiencies continuously feel hungry and become severely obese. Setmelanotide, the active substance contained in Imcivree, works by activating a pathway in the brain that controls appetite and feeling full. This can help patients eat less and lose weight. It also increases the number of calories that you burn by increasing resting energy. 

Hunger signaling

Setmelanotide is a small peptide drug. It acts like a hormone and stimulates the melanocortin 4 receptor (MC4). The MC4 receptor is present in the hypothalamus and manages the body's energy balance by processing energy-related metabolic signals. It is critical to appetite, glucose metabolism, energy homeostasis, blood pressure, heart rate and body-weight control.

When activated, the MC4 sends out commands that cause us to feel full. The cycle goes like this: When our energy levels drop the hypothalamus produces a hunger hormone (NYP or AGRP) that inactivates the MC4 receptor and we get hungry. After we eat, another hormone (α-MSH) binds to the active site on the MC4, replacing the hunger hormone and turning the receptor back on which tells our brain that we are full.

Problems occur with poor diet or possible mutations which inactivate the MC4 receptor, causing people to feel constantly hungry. This makes the MC4 a prime target for anti-obesity drugs, such as setmelanotide, that act as a master switch, switching on MC4 to control hunger. Treatment with setmelanotide could be another option for obese patients with diet induced obesity or defects in the leptin–melanocortin signaling pathway.

Problems with diet-induced obesity on melanocortin signaling

  • High-fat diets can damage regions of the hypothalamus that regulate and control energy homeostasis.
  • High-fat diets can induce hypothalamic injury with inflammation, gliosis and neuronal loss.
  • Obesity induces activation of the immune system and inflammation, which impacts many organs including adipose tissue, pancreas, liver, skeletal muscle and the brain.
  • In obesity, increased circulating saturated fatty acids and loss of HDL promotes hypothalamic inflammation and altered mitochondrial function in the hypothalamus.
  • In obesity, inflammation-induced changes in the blood-brain-barrier may contribute to neuronal injury and decreased regeneration of neurons relevant to energy homeostasis. 
  • Diet induced obesity can disrupt mitochondrial function and suppress the nutrient-dependent excitability of POMC neurons.
  • In obesity, disrupted insulin signaling by inflammation disrupts signaling in POMC neurons, thereby resulting in insulin and leptin resistance.

Obesity caused by diet or by POMC genetic deficiency shows disruption to the normal hypothalamic functions that control metabolic balance. Studies have shown that Setmelanotide given to obese individuals with leptin or insulin resistance causes decrease in hunger and increase in weight loss. Moreover, obese patients with POMC deficiency also have decrease of hunger and substantial weight loss when treated with Setmelanotide.

These studies suggest that, in addition to obesity due to POMC or leptin deficiency, Setmelanotide, alone or in combination with GLP-1 agonists, may also be beneficial for treatment of obesity and diabetes. Combination therapy of drugs acting on different pathways can offer synergistic effects on obesity treatment.

Screen Shot 2021-08-19 at 1.23.02 PM


Can increase resting energy metabolism in obese patients who were not tested for genetic causes of obesity 

  • Can shift energy source to fat in obese individuals
  • Can increases the number of calorie burn
  • Can reduce hunger
  • Can induce weight loss
  • Can improve insulin and leptin sensitivity 
  • Can help regulate and control energy balance

Side Effects

Adverse effects associated with the use of Setmelanotide may include, but are not limited to, the following:

  • injection site reactions
  • skin hyperpigmentation (tanning)
  • nausea
  • headache
  • diarrhea
  • abdominal pain
  • back pain
  • fatigue
  • vomiting
  • depression
  • upper respiratory tract infection
  • spontaneous penile erection


Transformyou offers consultations for anyone looking into their medical weight loss options. In the consultations, we work together to develop a medical weight loss plan that is safe and effective for you. Schedule your consultation today!

 All patients always work directly with one of our physicians to ensure patient safety and confidentiality.


Baldini, G., & Phelan, K. D. (2019). The melanocortin pathway and control of appetite-progress and therapeutic implications, Journal of Endocrinology, 241(1), R1-R33. Retrieved Aug 17, 2021, from https://joe.bioscientifica.com/view/journals/joe/241/1/JOE-18-0596.xml

Chen KY, Muniyappa R, Abel BS, Mullins KP, Staker P, Brychta RJ, Zhao X, Ring M, Psota TL, Cone RD, Panaro BL, Gottesdiener KM, Van der Ploeg LH, Reitman ML, Skarulis MC. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab. 2015 Apr;100(4):1639-45. doi: 10.1210/jc.2014-4024. 

 Markham A. Setmelanotide: First Approval. Drugs. 2021 Feb;81(3):397-403. doi: 10.1007/s40265-021-01470-9. PMID: 33638809.

Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. 

Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pépin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O'Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clément K, Farooqi IS, Van der Ploeg LHT. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017 Oct;6(10):1321-1329. doi: 10.1016/j.molmet.2017.06.015. 

Baldini G, Phelan KD. The melanocortin pathway and control of appetite-progress and therapeutic implications. J Endocrinol. 2019 Apr 1;241(1):R1-R33. doi: 10.1530/JOE-18-0596. PMID: 30812013; PMCID: PMC6500576.

do Carmo JM, da Silva AA, Rushing JS, Pace B, Hall JE. Differential control of metabolic and cardiovascular functions by melanocortin-4 receptors in proopiomelanocortin neurons. Am J Physiol Regul Integr Comp Physiol. 2013 Aug 15;305(4):R359-68. doi: 10.1152/ajpregu.00518.2012. 

Ayers KL, Glicksberg BS, Garfield AS, Longerich S, White JA, Yang P, Du L, Chittenden TW, Gulcher JR, Roy S, Fiedorek F, Gottesdiener K, Cohen S, North KE, Schadt EE, Li SD, Chen R, Van der Ploeg LHT. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2601-2612. doi: 10.1210/jc.2018-00258. 

Kühnen P, Krude H, Biebermann H. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment. Trends Mol Med. 2019 Feb;25(2):136-148. doi: 10.1016/j.molmed.2018.12.002. 

Nargund RP, Strack AM, Fong TM. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J Med Chem. 2006 Jul 13;49(14):4035-43. doi: 10.1021/jm058241a. PMID: 16821763.

Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C:Oraladministration of glucagon-like peptide 1 or peptide YY 3-36affects food intake in healthy male subjects. Am J Clin Nutr. 2010 Oct,92:810–817 https://doi.org/10.3945/ajcn.2010.29663

Clement K, Biebermann H, Farooqi IS et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018; 24: 551-555

Kong Y. Chen, Ranganath Muniyappa, Brent S. Abel, Katherine P. Mullins, Pamela Staker, Robert J. Brychta, Xiongce Zhao, Michael Ring, Tricia L. Psota, Roger D. Cone, Brandon L. Panaro, Keith M. Gottesdiener, Lex H.T. Van der Ploeg, Marc L. Reitman, Monica C. Skarulis, RM-493, a Melanocortin-4 Receptor (MC4R) Agonist, Increases Resting Energy Expenditure in Obese Individuals, The Journal of Clinical Endocrinology & Metabolism, Volume 100, Issue 4, April 2015, Pages 1639–1645, https://doi.org/10.1210/jc.2014-4024 ***

Pan, J. Guo, and Z. Su, "Advances in understanding the interrelations between leptin resistance and obesity," Physiol. Behav., vol. 130, pp. 157-169, May 2014.